第14回DIA日本年会

Lots of efforts have been made by academia, industry and regulatory agencies, in order to deliver innovative drugs to patents quickly. In this session, representative from FDA, EMA and MHLW will introduce their own activities as well as examples and they will discuss future direction under the recent high-uncertainly environment. The discussion includes their accelerated approval process (ie. FDA: Breakthrough designation, EU: PRIME and Japan: Sakigake) would how to be applied to accelerate appropriate medicine to patients. Also, how efficacy and safety of new therapy to rare disease, where usually typical double-blind trial is difficult to be conducted, is to be evaluated with sufficient validity from scientific and ethical point of views, in order to be delivered to the patients. Efforts by regulatory authorities to incorporate emerging novel science and regulatory science into the processes to establish new medicine, as well as the various collaboration among academia, industry and regulatory agencies globally, will be discussed by the presenters as panel discussion format.